Cadrenal Therapeutics, INC. (CVKD) — 8-K Filings

All 8-K filings from Cadrenal Therapeutics, INC.. Browse 27 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (27)

Cadrenal Therapeutics Files 8-K on Warrants and Equity — Apr 1, 2026 Risk: medium
Cadrenal Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting a material definitive agreement and unregistered sales of equity securities. The filing inc
8-K Filing — Mar 31, 2026
8-K Filing — Dec 23, 2025
8-K Filing — Dec 16, 2025
8-K Filing — Dec 11, 2025
Cadrenal Therapeutics Announces Executive Changes and Board Updates — Dec 1, 2025 Risk: medium
Cadrenal Therapeutics, Inc. announced on November 24, 2025, the departure of Dr. Michael L. R. Freeman from his role as Chief Medical Officer. The company also
Cadrenal Therapeutics Files 8-K — Nov 18, 2025 Risk: low
On November 18, 2025, Cadrenal Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 822 A1A Nor
Cadrenal Therapeutics Files 8-K on Security Holder Votes — Sep 24, 2025 Risk: low
Cadrenal Therapeutics, Inc. filed an 8-K on September 24, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain sp
8-K Filing — Sep 15, 2025
Cadrenal Therapeutics Files 8-K — Aug 5, 2025 Risk: medium
Cadrenal Therapeutics, Inc. filed an 8-K on August 5, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specif
Cadrenal Therapeutics Reports Director/Officer Changes & More — Jul 18, 2025 Risk: medium
Cadrenal Therapeutics, Inc. filed an 8-K on July 18, 2025, reporting events as of July 15, 2025. The filing indicates changes related to directors and officers,
Cadrenal Therapeutics Files 8-K — Apr 17, 2025 Risk: low
Cadrenal Therapeutics, Inc. filed an 8-K on April 17, 2025, reporting other events and financial statements. The filing does not contain specific details about
Cadrenal Therapeutics Files 8-K: Material Agreement & Other Events — Mar 4, 2025 Risk: medium
On March 3, 2025, Cadrenal Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statement
Cadrenal Therapeutics Files 8-K on Executive Changes — Feb 7, 2025 Risk: low
On February 4, 2025, Cadrenal Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also include
Cadrenal Therapeutics Files 8-K: Agreements, Equity Sales, and More — Nov 4, 2024 Risk: medium
On November 1, 2024, Cadrenal Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company al
Cadrenal Therapeutics Files 8-K Report — Oct 24, 2024 Risk: low
On October 24, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events a
Cadrenal Therapeutics Files 8-K — Sep 25, 2024 Risk: medium
Cadrenal Therapeutics, Inc. filed an 8-K on September 25, 2024, to report on several events. The filing includes information related to Regulation FD disclosure
Cadrenal Therapeutics Faces Delisting Concerns — Sep 5, 2024 Risk: high
Cadrenal Therapeutics, Inc. filed an 8-K on September 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is in
Cadrenal Therapeutics Acquires Subsidiary Cadrenal Biologics — Aug 20, 2024 Risk: low
Cadrenal Therapeutics, Inc. announced on August 19, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of its subsidiary, C
Cadrenal Therapeutics Files 8-K — Aug 16, 2024 Risk: medium
Cadrenal Therapeutics, Inc. filed an 8-K on August 16, 2024, to report material modifications to the rights of security holders and other events. The filing ind
Cadrenal Therapeutics Files 8-K with Financial Updates — Aug 8, 2024 Risk: low
On August 7, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and
Cadrenal Therapeutics Files 8-K Report — Aug 6, 2024 Risk: low
On August 6, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also included Financial Sta
Cadrenal Therapeutics Appoints New CMO, Elects Directors — Jul 31, 2024 Risk: medium
Cadrenal Therapeutics, Inc. announced on July 29, 2024, the appointment of Dr. David J. Recker as Chief Medical Officer and the election of Dr. Recker and Ms. J
Cadrenal Therapeutics Files 8-K with Financials — Apr 9, 2024 Risk: low
On April 9, 2023, Cadrenal Therapeutics, Inc. filed an 8-K report detailing its financial statements and exhibits. The company, incorporated in Delaware, is inv
Cadrenal Therapeutics Enters Material Definitive Agreement — Mar 12, 2024 Risk: medium
On March 11, 2024, Cadrenal Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related
Cadrenal Therapeutics Faces Delisting Notice — Mar 5, 2024 Risk: high
Cadrenal Therapeutics, Inc. filed an 8-K on March 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is also f
Cadrenal Therapeutics (CVKD) Confirms Nasdaq Listing in 8-K Filing — Feb 12, 2024 Risk: low
Cadrenal Therapeutics, Inc. (CVKD) filed an 8-K on February 12, 2024, reporting an event that occurred on February 6, 2024. This filing primarily updates the co

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX